{"type":"trials","record":{"id":42076,"source_id":"clinicaltrials-gov","external_id":"NCT02289924","title":"Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy","brief_summary":"The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of \"naïve\" patients","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Bayer","enrollment":912,"countries":["Italy"],"start_date":"2015-01-09","completion_date":"2019-07-08","last_update_date":"2023-11-07","source_url":"https://clinicaltrials.gov/study/NCT02289924","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"PERSEUS-IT","age_range":null,"comparator":null,"organization":"Bayer","interventions":["Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change of visual acuity from baseline to 12 months. — Baseline to 12 months","Mean change of visual acuity from baseline to 24 months. — Baseline to 24 months","Number of clinical visits (visits for injections) — At 12 and 24 months","Number of monitoring visits (visits only for diagnostic purposes, but without injections) — At 12 and 24 months","Number of combined visits (visits for monitoring and injection) — At 12 and 24 months","Number of post-injection monitoring visits (visits only for safety checks after injection) — At 12 and 24 months","Number of visits outside the study center after 12 and 24 months — At 12 and 24 months","Number of optical coherence tomography (OCT) assessments per patient — At 12 and 24 months","Number of visual acuity tests — At 12 and 24 months","Number of fundoscopy examinations — At 12 and 24 months","Mean time between the injections and visits — At 12 and 24 months","Mean time between the first symptoms and diagnosis — Up to 24 months","Mean time from indication of the Eylea treatment by the treating physician to treatment — Up to 24 months","Proportion of patients with no fluid — At 4,12 and 24 months","Mean change in retinal thickness from baseline — Baseline and at 4,12 and 24 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Wet Macular Degeneration","Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02289924","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2015-01-09 to 2019-07-08","comparator":null,"confidence":"structured-source","population":"ALL","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.916Z","intervention":["Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)"],"participants":912,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change of visual acuity from baseline to 12 months. — Baseline to 12 months","Mean change of visual acuity from baseline to 24 months. — Baseline to 24 months","Number of clinical visits (visits for injections) — At 12 and 24 months","Number of monitoring visits (visits only for diagnostic purposes, but without injections) — At 12 and 24 months","Number of combined visits (visits for monitoring and injection) — At 12 and 24 months","Number of post-injection monitoring visits (visits only for safety checks after injection) — At 12 and 24 months","Number of visits outside the study center after 12 and 24 months — At 12 and 24 months","Number of optical coherence tomography (OCT) assessments per patient — At 12 and 24 months","Number of visual acuity tests — At 12 and 24 months","Number of fundoscopy examinations — At 12 and 24 months","Mean time between the injections and visits — At 12 and 24 months","Mean time between the first symptoms and diagnosis — Up to 24 months","Mean time from indication of the Eylea treatment by the treating physician to treatment — Up to 24 months","Proportion of patients with no fluid — At 4,12 and 24 months","Mean change in retinal thickness from baseline — Baseline and at 4,12 and 24 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42076","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}